Back to Trades
Grant4
Denali Therapeutics Inc.
DNLI
Total Value
$475.9K
Company Information
- Company Name
- Denali Therapeutics Inc.
- Ticker Symbol
- DNLI
- CIK
- 0001714899
Insider Information
- Role
- Director
- Location
- SOUTH SAN FRANCISCO, CA
Director
Filing Details
- Filing Date
- Nov 6, 2025
- Transaction Date
- Nov 4, 2025
- Accession Number
- 0001816206-25-000007
- Form Type
- 4
Non-Derivative Transactions
| Date | Security | Shares | Price | Type | Value |
|---|---|---|---|---|---|
| Nov 4, 2025 | Common Stock | 10,632 | — | Grant/Award | — |
Derivative Transactions
| Date | Security | Shares | Exercise Price | Type | Value |
|---|---|---|---|---|---|
| Nov 4, 2025 | Derivative | 31,897 | $14.92 | Grant/Award | $475.9K |
Footnotes
- (F1)Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. The RSU award vests over a four-year period, with 1/4th of the shares vesting on each anniversary of the grant date (or, for the last tranche that otherwise would vest on the fourth anniversary of the grant date, on such anniversary or, if earlier, on the day prior to the Company's next annual meeting of stockholders occurring after the third anniversary of the grant date), provided that he remains a non-employee director through the applicable vesting date.
- (F2)Includes 10,632 unvested RSUs.
- (F3)25% of the shares subject to the option shall vest on November 4, 2026, and an additional 1/48 of the shares subject to the option vest each month thereafter, subject to the Reporting Person remaining a non-employee director of the Issuer through each such date